Expression of anoctamin 7 in nuclear factor kappa B signal pathway and its clinical significance in prostate cancer

Objective To study the Expression of anoctamin 7 (ANO7) in the nuclear factor kappa B (NF-κB) signal pathway and its clinical significance in prostate cancer. Methods NF-κB signal pathway activated cell and animal model were constructed using tribbles homolog1 (TRIB1) overexpressed prostate cancer cell line. NF-κB signal pathway inhibited cell model was constructed using NF-κB signal pathway inhibitor. Western blotting and real-time quantitative polymerase chain reaction (Real-time PCR) and immunohistochemistry (IHC) were used to analyze the effect of NF-κB signal pathway on the regulation of ANO7 expression and the relationship between ANO7 expression and clinicopathological features in prostate cancer. Results ANO7 expression was up-regulated in the NF-κB signal pathway-activated cell and animal models. ANO7 expression was down-regulated in the NF-κB signal pathway-inhibited cell models. The high expression level of ANO7 was 45.8% in tumor tissues compared with 85.7% in adjacent non-cancerous tissues, with statistical significance (χ2=7.258, P<0.01). The expression of ANO7 was significantly correlated with Gleason score and pathological grade (χ2=19.797, 19.797, P<0.01). Similar results were obtained from The Cancer Genome Atlas (TCGA) and the Taylor database. Kaplan-Meier analysis found that ANO7 was significantly associated with the patients’prognosis in the Taylor database (P<0.01). Multivariate analysis found that ANO7 (P<0.05), Gleason score (P<0.01) and pathological grade (P<0.01) were independent predictors of prostate cancer using the Cox regression model in the cohort affecting prostate cancer prognosis. Conclusion NF-κB signal pathway regulates ANO7 expression in prostate cancer and the expression of ANO7 is closely related to prostate cancer. Key words: Anoctamin 7; Nuclear factor kappa B signal pathway; Prostate cancer; Prognosis